A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC is a phase 1/2 interventional study registered as NCT07547553 by Huahui Health, with 30 participants planned, started 2026-05-19 and due to reach its primary completion in 2028-10-30. Interventions recorded: Will receive HH-009 injection 20 mg/kg, Q3W and Will receive HH-009 injection 30 mg/kg, Q3W.